Home › Marginal Zone Lymphoma
Pag-aaral pangklinika para sa Marginal Zone Lymphoma na nagre-recruit sa U.S.
54 pag-aaral para sa Marginal Zone Lymphoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Durham, NC12 pag-aaral
- New York City, NY10 pag-aaral
- Milwaukee, WI9 pag-aaral
- Baldwin Park, CA9 pag-aaral
- Columbus, OH8 pag-aaral
- Boston, MA8 pag-aaral
- Seattle, WA8 pag-aaral
- Edison, NJ8 pag-aaral
- Houston, TX8 pag-aaral
- Miami, FL7 pag-aaral
- Rochester, MN7 pag-aaral
- Denver, CO7 pag-aaral
- Nashville, TN7 pag-aaral
- Jacksonville, FL6 pag-aaral
- Salt Lake City, UT6 pag-aaral
- Dallas, TX5 pag-aaral
- Washington, DC5 pag-aaral
- Atlanta, GA5 pag-aaral
- Portland, OR5 pag-aaral
- Cleveland, OH5 pag-aaral
- Queens, NY5 pag-aaral
- Greenburgh, NY5 pag-aaral
- St. Louis, MO5 pag-aaral
- Chicago, IL5 pag-aaral
- Cincinnati, OH4 pag-aaral
- Los Angeles, CA4 pag-aaral
- Minneapolis, MN4 pag-aaral
- Staten Island, NY4 pag-aaral
- New Rochelle, NY4 pag-aaral
- Philadelphia, PA4 pag-aaral
- Tampa, FL4 pag-aaral
- Buffalo, NY4 pag-aaral
- Richmond, VA3 pag-aaral
- New Haven, CT3 pag-aaral
- Providence, RI3 pag-aaral
- East Norwalk, CT3 pag-aaral
- Ann Arbor, MI3 pag-aaral
- Cedar Rapids, IA3 pag-aaral
- Scottsdale, AZ3 pag-aaral
- Mountain View, CA3 pag-aaral
Ayos sa estado
- Arizona5 pag-aaral
- California18 pag-aaral
- Colorado8 pag-aaral
- Connecticut4 pag-aaral
- Florida15 pag-aaral
- Georgia6 pag-aaral
- Illinois6 pag-aaral
- Iowa4 pag-aaral
- Kansas3 pag-aaral
- Maryland6 pag-aaral
- Massachusetts11 pag-aaral
- Michigan5 pag-aaral
- Minnesota11 pag-aaral
- Missouri5 pag-aaral
- New Jersey9 pag-aaral
- New York14 pag-aaral
- North Carolina15 pag-aaral
- Ohio13 pag-aaral
- Oregon5 pag-aaral
- Pennsylvania5 pag-aaral
- Rhode Island3 pag-aaral
- Tennessee8 pag-aaral
- Texas12 pag-aaral
- Utah6 pag-aaral
- Virginia4 pag-aaral
- Washington9 pag-aaral
- Wisconsin10 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 110 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT00923507Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT04840602A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT06149286A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07101328A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07231952A Study of ARC-02 in B-cell NHL
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT07691606Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT07583810Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 28, 2026 · NCT01137643Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT06533579A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT07029217Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT04545762A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 15, 2026 · NCT07424833Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 15, 2026 · NCT06796998CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 9, 2026 · NCT06026319A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05006716Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07763210Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06350318Epco, Zanu, Ritux for R/R FL or MZL
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06563596Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT05296070Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07225439Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT04792502HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT06792825AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT06340737LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Nagre-recruitPhase 1
Edad 18 hanggang 81 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT05990465A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT06708897Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.